The pros and cons of the COVID-19 vaccine Sinovac in various countries is still ongoing. However, the CoronaVac vaccine program produced by Sinovac is starting to be implemented in various parts of the world.
Quoted from CNN, Turkish President Recep Tayyip Erdogan was injected with a vaccine made by Sinovac on Thursday (14/1/2021). Previously, on Wednesday (13/1/2021) President Joko Widodo received CoronaVac after the vaccine received Emergency Use Authorization (EUA) status from the BPOM.
Several countries have signed purchase agreements the COVID-19 vaccine Sinovac. However, with the latest research evidence on the effectiveness, several countries intend to re-evaluate the use of CoronaVac.
“With so many countries planning or already ordering Sinovac, people’s desire for the vaccine may drop and start questioning its effectiveness. This has the potential to hinder the vaccine delivery program,” said Chinese health systems expert Yanzhong Huang.
A. Reasons for the COVID-19 Sinovac vaccine in various countries
The reason some countries choose the Sinovac COVID-19 vaccine
- Cheaper price
- It is easier to distribute because it does not require expensive storage facilities, unlike Pfizer-BioNTech and Moderna.
Quoted by Reuters, Sinovac has made agreements with at least six countries. Sinovac provides 46 million doses of vaccine in Brazil, 50 million in Turkey, and 7.5 million for Hong Kong.
Sinovac is also providing 40 million concentrations of vaccine for Hong Kong which will be produced in-house. Thailand has ordered two million Sinovac vaccines, which will start receiving 200,000 doses in February. Meanwhile, the Philippines has ordered 25 million Sinovac dosin which will arrive in February 2021.
B. Reasons for Covid-19 Sinovac vaccine counter in various countries
Here are the reasons for some countries to refuse or reconsider the use of the COVID-19 Sinovac vaccine
- The so-called efficacy is lower than the vaccines produced by Pfizer-BioNTech or Moderna.
- Evidence of efficacy differs in each country that is the location for the phase three trial of the COVID-19 CoronaVac vaccine produced by Sinovac.
The results of research in Brazil show the efficacy of the Sinovac vaccine is only 50.38 percent, only slightly higher than the 50 percent required by the World Health Organization, WHO. This result is also lower than the report in early January 2021 of 78 percent.
With this result, the efficacy of Sinovac is lower than Pfizer-BioNTech and Moderna which reached 95 percent. The efficacy rate for Sinovac is also smaller than Sputnik V at 91 percent, AstraZeneca 70 percent, Sinopharm 98.34 percent.
Quoted from the Straits Times, the Singapore government is reviewing the plan to give Sinovac to the public. Singapore has previously agreed to purchase a number of doses of Sinovac. Malaysia and Hong Kong have done similar things regarding usage the COVID-19 vaccine Sinovac.
The different efficacy results in each country are a factor the pros and cons of the COVID-19 vaccine Sinovac in various other countries. Indonesia reported an efficacy rate of 65.3 percent and Turkey 91.25 percent.
Brazil reported 50.38 percent of very mild cases of COVID-19. The efficacy rate increases to 78 percent in mild to severe cases. Sinovac spokesman briefly explained this phenomenon.
“These results were obtained from different populations, places and mortality rates. These are the conditions that ultimately lead to quite a large difference in results,” said a company spokesman for Sinovac.
Efficacy the COVID-19 vaccine it is very important to build body resistance against viruses and create herd immunity. With improved immunity, it is hoped that various economic sectors, including tourism, will recover soon.
The pros and cons of the COVID-19 vaccine Sinovac in various countries can be difficult to end. However, the various opinions that have emerged should not prevent the desire to get the COVID-19 vaccine.
Watch Video “The third week of January, 44 thousand health workers in West Java will be vaccinated against corona“
(row / pal)